Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: A meta-analysis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Abhenil,Mittal

第一单位： Division of Medical Oncology and Haematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, ON, Canada.

作者： Abhenil,Mittal ^[1] ; Faris,Tamimi ^[1] ; Consolacion,Molto ^[1] ; Nicholas,Meti ^[2] ; Laith,Al-Showbaki ^[3] ; Brooke E,Wilson ^[4] ; Eitan,Amir ^[5]

作者单位： Division of Medical Oncology and Haematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, ON, Canada. ^[1] Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada. ^[2] Division of Hematology and Medical Oncology, Department of Medicine, University Hospital and School of Medicine, University of Jordan, Amman, Jordan. ^[3] Collaboration for Cancer Outcomes, Research and Evaluation, South West Clinical School, University of New South Wales, Liverpool, NSW, Australia; Department of Oncology, Queen's University, Kingston, Ontario, Canada. ^[4] Division of Medical Oncology and Haematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, ON, Canada. Electronic address: eitan.amir@uhn.ca. ^[5]

关键词 Disease-free survival Dual HER2-targeted therapy Meta-analysis Neoadjuvant therapy Randomized controlled trial